Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation) - Goodman, Shaun G.; Hacke, Werner (Journal of the American College of Cardiology, 2014)
Gesehen am 08.10.2014